what happened
Vaccine Developer for Coronavirus Novavaxsay (NASDAQ: NVAX) ‘s share blew more than 30% higher in trading after the market on Thursday in response to good news about its candidate for vaccine.
Approximately
Novavax announced after market hours that the NVx-CoV2373 reached its primary endpoint and showed more than 89% efficacy in a Phase 3 clinical trial in the United Kingdom. Serious, serious and medically-attended updates were at low levels.
The biotechnology also reported encouraging results for a Phase 2b study undertaken in South Africa, although the efficacy was lower (60% in the case of HIV-negative participants, representing 94% of the study).
Image Source: Getty Images.
It is important that NVX-CoV2373 is the first vaccine to show not only high clinical efficacy against COVID-19 but also significant clinical efficacy against the rapidly emerging British and South African variants, ” Stanley Erck, CEO, said. Evidence suggests that the two variants are more contagious than before.
Novavax is currently enrolling participants in a Phase 3 study of 30,000 men in Mexico and the USA. To date, the company has randomized more than 16,000 individuals.
Now what
Yes, the coronavirus vaccines currently authorized in the US – Modernsee mRNA-1273 and Pfizer and BioNTechBNT162b2 – shown higher efficiency than NVx-CoV2373. Yet 89% is extraordinarily high for any candidate for vaccinations, especially one that has developed so rapidly.
It looks like Novavax is almost certainly getting regulatory approval for NVx-CoV2373.